@article {WALKER1326, author = {KYLE M. WALKER and JANET POPE}, editor = {Alkassab, Firas and Molitor, Jerry A. and Shapiro, Lee S. and Fessler, Barri J. and Gran, Jan Tore and Goldberg, Avram and Medsger, Thomas A. and Valentini, Gabriele and Rodriguez-Reyna, Tatiana S. and Csuka, M.E. and Griffing, Leroy and Herrick, Ariane and Kari Connolly, M. and Vacca, Alessandra and Riemekasten, Gabriela and Wigley, Fredrick M. and Farge, Dominque and Johnson, Sindhu R. and Matucci-Cerinic, Marco and Czirjak, Laszlo and Toloza, Sergio Miguel Angel and Mahmud, Tafazzul H. and Frech, Tracy M. and Voskuyl, Alexandre E. and Merkel, Peter A. and Domsic, Robyn and Emery, Paul and Steen, Virginia and Rudnicka, Lidia and Denton, Christopher P. and Clements, Philip J. and Chatterjee, Soumya and Kahaleh, Bashar and Hayat, Samina and Mouthon, Luc and Lafyatis, Robert and Lally, Edward V. and Krieg, Thomas and Chung, Lorinda and Catoggio, Luis J. and Mayes, Maureen D. and Anderson, Marina E. and Silver, Richard and Proudman, Susanna and Seibold, James R. and Sen{\'e}cal, Jean-Luc and Stevens, Wendy and Hachulla, Eric and Inanc, Murat and Wollheim, Frank and Distler, Oliver and Katsumoto, Tamiko R. and Hsu, Vivien and Collier, David H. and Furst, Daniel and McKown, Kevin and Khanna, Dinesh and Volkov, Suncica and Mathieu, Alessandro and Baron, Murray and Kaminska, Elzbieta A. and Khalidi, Nader A. and Hudson, Marie and Markland, Janet and Masetto, Ariel and Docherty, Peter}, title = {Expert Agreement on EULAR/EUSTAR Recommendations for the Management of Systemic Sclerosis}, volume = {38}, number = {7}, pages = {1326--1328}, year = {2011}, doi = {10.3899/jrheum.101262}, publisher = {The Journal of Rheumatology}, abstract = {Objective. The European League Against Rheumatism/EULAR Scleroderma Trials and Research group (EULAR/EUSTAR) has published recommendations for the management of systemic sclerosis (SSc). Members of the Scleroderma Clinical Trials Consortium and the Canadian Scleroderma Research Group were surveyed regarding their level of agreement with the recommendations. Methods. A survey containing the 14 EULAR/EUSTAR recommendations asked participants to indicate their level of agreement with each on a 10-point scale, from 0 (not at all) to 9 (completely agree). The survey was sent to 117 people, and 66 replies were received (56\% response rate). Results. Exceptions to generally high agreement included the use of iloprost and bosentan for digital vasculopathy, methotrexate for skin involvement, and bosentan and epoprostenol for pulmonary arterial hypertension (PAH; all \< 69\% agreement, defined as >= 7 rating). Vasculopathy and PAH treatment had differences in agreement between North America and Europe (p \< 0.006). Respondents who were EULAR/EUSTAR recommendation authors shared a similar level of agreement compared to those who were not, except for the use of proton pump inhibitors for the prevention of SSc-related gastroesophageal reflux disease, esophageal ulcers, and strictures. Conclusion. EULAR/EUSTAR recommendations were relatively well accepted among SSc experts. Overall reduced agreement may be due to the modest efficacy of some agents (such as methotrexate for the skin). Some regional disagreement is likely because of access differences.}, issn = {0315-162X}, URL = {https://www.jrheum.org/content/38/7/1326}, eprint = {https://www.jrheum.org/content/38/7/1326.full.pdf}, journal = {The Journal of Rheumatology} }